PDCD1 and non-small cell lung carcinoma: Therefore, we carried out a systematic review and meta‐analyses to address the differences between anti‐PD‐1 and anti‐PD‐L1 antibodies in first‐line therapy of metastatic NSCLC patients through adjusted indirect comparison to minimize the potential bias regarding overall response rate (ORR), progression‐free survival (PFS), overall survival (OS) and toxicity grade 3–5.